Rapport Therapeutics (RAPP) Reiterated at Market Outperform by Citizens on Positive Ph2 Results

September 23, 2026 4:48 AM EDT Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $80.00 price target on Rapport Therapeutics (NASDAQ: RAPP).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login